Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non‐small cell lung cancer

Abstract Background Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residual disease (MRD) in lung cancer after definitive treatment. Herein, we investigated the value of ctDNA in prognosing risk of relapse and monitoring the effect of adjuvant therapy in surgical non‐small cell lung cancer (NSCLC). Methods We enrolled 58 NSCLC patients in a real‐world setting, and 58 tumor tissues and 325 plasma samples were analyzed. Tumor tissues and plasma samples were subjected to targeted next‐generation sequencing (NGS) of 1021 cancer‐related and ultra‐deep targeted NGS covering 338 genes, respectively. Results ctDNA was detected in 31.0% of cases at the first postoperative time, which was associated with advanced tumor stage, T stage and KEAP1 or GRIN2A mutations in tissues. ctDNA positivity at landmark and longitudinal indicated the shorter disease‐free survival. For patients with ctDNA positivity at the first postoperative time, regardless of adjuvant therapy, all patients who were persistently ctDNA positive during postoperative surveillance had disease recurrence. Among the patients who were ctDNA negative, only two patients (15.4%, 2/13) receiving adjuvant therapy relapsed, while one patient (50.0%, 1/2) without adjuvant therapy relapsed. For the first postoperative ctDNA negative patients, the recurrence rate of patients with adjuvant therapy was and higher than without adjuvant therapy (22.6% 7/31 vs. 11.1% 1/9). The patients who became ctDNA positive may also benefit from intervention therapy. Conclusion Postoperative ctDNA is a prognostic marker, and ctDNA‐detection may facilitate personalized adjuvant therapy, and applying adjuvant therapy to the patients with detectable ctDNA could bring clinical benefits for them.